TITLE

COMMENATRY: Review: ACE inhibitors reduce mortality and cardiovascular endpoints in stable coronary artery disease

AUTHOR(S)
Stone, Peter H.
PUB. DATE
September 2006
SOURCE
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p32
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents comments on a study by N. Danchin and colleagues on the protective role of Angiotensin-converting enzyme inhibitor in the prevention of coronary artery disease. According to the author, the study contained many inconsistencies that was not explained by the researchers. However, the role of the angiotensin system contributing to vascular pathologic conditions is proved by the study.
ACCESSION #
22493470

 

Related Articles

  • Interaction Between Aspirin and ACE Inhibitors: Resolving Discrepancies Using a Meta-Analysis. Takkouche, B.; Etminan, M.; Caamaño, F.; Rochon, P.A. // Drug Safety;Mar2002, Vol. 25 Issue 5, p373 

    Background: Recently, studies have attempted to explore the interaction between ACE inhibitors and aspirin (acetylsalicylic acid) when both drugs are used concomitantly to reduce mortality in patients with coronary artery disease. Results have been conflicting due, in part, to sub-optimal...

  • Importance of RAA System and the Treatment of Patients with ACE Inhibition After Myocardial Infarction. Ray, S. G.; McAlpine, H. M.; Morton, J. J.; Leckie, B.; Dargie, H. J. // Angiology;Apr1991, Vol. 42 Issue 4, p268 

    There is activation of the renin angiotensin system after both complicated and uncomplicated myocardial infarction. Angiotensin II increases myocardial oxygen consumption whilst reducing coronary flow and is also directly toxic to the myocardium. Angiotensin converting enzyme inhibitors produce...

  • Tissue ACE Inhibitors for Secondary Prevention of Cardiovascular Disease in Patients With Preserved Left Ventricular Function: A Pooled Meta-analysis of Randomized Placebo-controlled Trials. Saha, Sandeep A.; Molnar, Janos; Arora, Rohit R. // Journal of Cardiovascular Pharmacology & Therapeutics;Sep2007, Vol. 12 Issue 3, p192 

    This article presents an analysis of published, randomized placebo-controlled clinical trials to evaluate the role of tissue angiotensin-converting enzyme inhibitors in secondary prevention of cardiovascular disease in patients with preserved left ventricular function. Considered as a...

  • Research Roundup. Linden, Belinda // British Journal of Cardiac Nursing;Feb2012, Vol. 7 Issue 2, p92 

    The article presents abstracts on cardiovascular nursing including "Gender differences in symptoms of myocardial ischaemia," by M. H. Mackay and colleagues, "Association of coronary CT angiography or stress testing with subsequent utilization and spending among medicare beneficiaries," by J. B....

  • Perindopril reduced cardiac events in stable coronary artery disease: COMMENTARY. Best, Patricia J. M.; Berger, Peter R. // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p31 

    The article comments on the study of the efficacy of perindopril in reducing cardiac event in stable coronary artery diseases. The supported the widespread use of the angiotensin-converting enzyme (ACE ) inhibitor ramipril to prevent cardiovascular events. However, several questions remained and...

  • ACE Inhibitors after Myocardial Infarction: Clinical and Economic Considerations. Davie, A.P. // PharmacoEconomics;2000, Vol. 17 Issue 3, p237 

    Economic analysis has been extensively used to guide the use of ACE inhibitors in chronic heart failure. More recently, it has been used to guide the use of ACE inhibitors after myocardial infarction. The results of major clinical trials leave us in no doubt that ACE inhibitors are useful in the...

  • Perindopril reduced cardiac events in stable coronary artery disease.  // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p31 

    The article focuses on the factors that help in reducing the cardiovascular events among patients with stable coronary artery disease. It examines if the angiotensin-converting enzyme (ACE) inhibitor perindopril reduce cardiac events in patients with stable coronary artery disease (CAD)....

  • ACE inhibitor-ARB combination no benefit.  // Pulse;11/4/2009, Vol. 69 Issue 35, p9 

    The article reports on the systematic review which shows that there is no benefit on the combination of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) for treatment of ischaemic heart disease in Great Britain. It states that patients who are taking both medicines...

  • Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention. Hamon, M.; Fradin, S.; Denizet, A.; Filippi-Codaccioni, E.; Grollier, G.; Morello, R. // Heart;Mar2003, Vol. 89 Issue 3, p321 

    Objective: To evaluate prospectively the influence of an angiotensin I converting enzyme (ACE) gene polymorphism on long term clinical outcome of patients with established coronary artery disease treated by percutaneous coronary intervention. Design and setting: Prospective observational study...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics